Adults under 50 who use marijuana may face a significantly higher risk of heart attack, according to a new study published in the Journal...

A randomized clinical trial published in JAMA Network Open  found that incorporating online group mindfulness sessions into buprenorphine treatment for opioid use disorder (OUD) significantly reduced opioid cravings compared to treatment as usual. The study, led by Dr. Zev Schuman-Olivier and colleagues from Cambridge Health Alliance and Harvard Medical School, examined the effectiveness of a 24-week virtual mindfulness-based program compared to a standard recovery support gr

Recent research suggests that semaglutide, a medication primarily used for type 2 diabetes and weight management, may also help reduce alcohol consumption. The study published in JAMA Psychiatry found that patients with alcohol use disorder (AUD) who were prescribed GLP-1 drugs, popularly known by their brand names Ozempic and Wegovy, had a significantly lower risk of hospitalization for alcohol-related issues. Background on Semaglutide and Liraglutide Semaglutide and liraglu

Alcohol, cannabis, and opioids the most prevalent substances reported in drug-related ED visits A new report from the Substance Abuse and...

A new report  from the Substance Abuse and Mental Health Services Administration (SAMHSA) on  Treatment Episode Data Set (TEDS) provides a detailed snapshot of substance use disorder treatment services across the United States. Findings are drawn from nearly 1.5 million treatment admissions and 1.4 million discharges reported in 2022 and show that 35.5% of admissions were for alcohol use, 16.9% were for heroin use, 13.9% were for methamphetamine use, 11.7% were for other opia

Findings from a new report from the Interagency Coordinating Committee for the Prevention of Underage Drinking (ICCPUD)  indicate that...

A new report  released by the Centers for Disease Control and Prevention (CDC)  found that overdose deaths in the United States still...

Each year, millions of Americans come in contact with the justice system–ranging from 911 calls, police encounters, and court proceedings...

Recent findings from a nationally representative survey found that only 44% of U.S. jails provide medications to treat opioid use...

Xylazine is a non-opioid sedative not approved for human use that is increasingly found as an adulterant in the illicit drug supply and...

Findings from JCOIN’s University of Kentucky Research Center and Methodology and Advanced Analytics Resource Center (MAARC) The number of...

CDC data shows a 10% drop in overdose deaths this year.

The overdose epidemic in the U.S. has surged, with over 106,000 deaths reported in 2023. While initially driven by opioids, recent trends...

Findings from JCOIN’s Coordination and Translation Center (CTC) A recent study published in the journal Victims & Offenders  explores the...

Recovery Management Checkups (RMC) are a structured intervention designed to improve substance use disorder (SUD) treatment engagement,...

Teen vaping trends are a growing concern. In 2023, 2.1 million young people in the U.S. were vaping, with many using flavored...

The video explainer on underage drinking highlights the risks and consequences of early alcohol use.

A new study  shows that adolescents are more prone to cannabis use disorder and its adverse effects than adults.  Led by Dr. Rachel Lees...

Findings from JCOIN’s Yale HIV Research Center The intersection of substance use disorders (SUD) and human immunodeficiency virus (HIV)...

Exercise is a safe and effective tool in addressing substance use disorders and depression.